Business Wire·Apr 14, 2026, 10:00 PM ET

HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock

HeartBeam, Inc. (NASDAQ: BEAT) priced an underwritten public offering of 12,500,000 common shares for total gross proceeds of $10 million.
The company granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments.
The offering is led by ClearCardio™, the company's first commercial customer, alongside executive leadership, board members, existing investors, & fundamental institutional investors.
The transaction is expected to close on or about April 16, 2026, subject to customary closing conditions.
Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the offering.
HeartBeam intends to use net proceeds to commercialize its FDA-cleared 12-lead synthesized ECG system, advance extended-wear patch & heart attack detection initiatives, enhance AI capabilities, & support working capital.
The offering was made pursuant to a shelf registration statement on Form S-3/A filed with the SEC on March 13, 2026, which became effective on March 17, 2026.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, & its 12-Lead ECG synthesis software received clearance in December 2025.
The company holds over 20 issued patents related to its technology enablement & aims to provide actionable cardiac insights outside of medical facilities.